clinical

Pierre Fabre Laboratories is exploring the potential of Artificial Intelligence to launch a new generation of clinical studies in dermo-cosmetics

From 100 to 600 patients: to support patients suffering from acne, Avène, Pierre Fabre Laboratories' leading brand, is strengthening the…

1 month ago

NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimers Disease at AD/PD 2026

March 10, 2026 08:05 ET  | Source: NKGen Biotech, Inc. SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen…

1 month ago

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent…

2 months ago

REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing ServicesBELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today…

2 months ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical…

2 months ago

AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics’ Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)

HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has…

2 months ago

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

February 22, 2026 16:00 ET  | Source: Dyne Therapeutics, Inc. - Late-breaking poster to feature new positive cardiopulmonary function results…

2 months ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease…

2 months ago

ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA…

2 months ago

FDA 510(k) Clearance Establishes Broad Intended Use for Copan’s PhenoMATRIX, Expanding Clinical Microbiology Capabilities

MURRIETA, Calif., Feb. 17, 2026 /PRNewswire/ -- Copan Group announced today that PhenoMATRIX®, its automated image assessment software used with…

2 months ago